Atopic dermatitis (AD) is one of the most common inflammatory skin conditions in humans. It frequently starts in early childhood, persists in adolescence and can also be present during adult life. Current estimates of AD prevalence are 15 – 30% in children and 2 – 10% in adults in developed countries (1). AD is a complex, pruritic, and usually eczematous inflammatory skin disease which likely involves a skin barrier dysfunction in concert with immunologic abnormalities driven by dendritic cells (DCs), T cells, eosinophils as well as different cytokine and chemokine circuits (1, 2). Between 80% and 90% of affected patients display elevated peripheral immunoglobulin E (IgE) levels and type I sensitizations to a limited set of characteristic allergens, usually termed extrinsic AD, while this association is not found in the smaller group of patients with so called intrinsic AD (3). The treatment of AD includes topical anti-inflammatory therapies such as topical corticosteroids and calcineurin inhibitors as well as systemic corticosteroids and cyclosporine for the treatment of more severe disease and flares.